A 24-year-old male developed cytogenetic relapse of chronic myeloid leukemia (CML) four years after allogeneic BMT. After a year of treatment with IFN-␣, he achieved a partial cytogenetic response. Treatment with donor leukocyte infusions (DLI) was given (total dose 1 ؋ 10 8 T lymphocytes/kg). Two months later, he developed acute GVHD (skin and liver), that improved with CsA and methylprednisolone and resulted in cytogenetic remission with complete donor chimerism. One month later he developed rhinocerebral mucormycosis and was successfully treated with surgical debridement and liposomal amphotericin B (total dose 12 g). This is the first case of mucormycosis described after DLI. Keywords: mucormycosis; donor leukocyte infusion; liposomal amphotericin B Fungal infection remains a major cause of morbidity and mortality in patients undergoing BMT.
Fungal infection remains a major cause of morbidity and mortality in patients undergoing BMT. 1 Opportunistic fungal infections such as mucormycosis are likely to become increasingly recognized in the post-BMT patient population. 2 DLI is an effective therapy for patients who experience a relapse with leukemia after BMT. 3, 4 We describe a patient who developed rhinocerebral mucormycosis after DLI for treatment of CML in post-BMT relapse, successfully resolving after therapy with liposomal amphotericin B and surgical debridement.
Case report
A 24-year-old man with chronic myeloid leukemia (CML) was transferred to our institution for BMT. He was diagnosed in November 1988 and initially treated with hydroxyurea. He received an allogeneic BMT from his HLA-identical sister in October 1989; 1.6 ϫ 10 days). CsA and methotrexate were used for GVHD prophylaxis. Peripheral blood counts showed neutrophil (Ͼ0.5 ϫ 10 9 /l) and platelet (Ͼ25 ϫ 10 9 /l) engraftment at ϩ30 and ϩ 45 days post-transplant, respectively. There was no evidence of acute or chronic GVHD. The patient was in morphologic and cytogenetic complete remission until January 1994 (4 years and 4 months post-BMT), when cytogenetic analysis was performed on bone marrow that revealed Ph positive in 14/20 (70%) of metaphases. IFN-␣ treatment was started, 1.5 MU s.c. daily. However, cytogenetic analysis 6 and 12 months later showed only a partial cytogenetic response (Phϩ in 40% and 30% metaphases, respectively). Treatment with DLI was started in February 1995. Donor leukocyte collection as performed by apheresis and divided into fractions. DLI were given to the patient six different times without prophylactic immunosuppressive therapy. A total dose of 1 ϫ 10 8 T lymphocytes/kg was infused and IFN-␣ 1.5 MU s.c. daily was added.
Two months after the first DLI, he developed signs of GVHD. The GVHD reached grade II, including a generalized skin rash and liver involvement (confirmed by skin and liver biopsies) with hyperbilirubinemia (peak level 2.4 mg/dl). Immunosuppressive treatment with CsA and methylprednisolone was employed and the GVHD responded promptly, with complete resolution.
Cytogenetic studies following the DLI showed a normal karyotype 46, XX [20] and BCR-ABL negativity (by FISH). Hemopoietic chimerism was assessed in bone marrow and peripheral blood with PCR amplification of the MCT 118 hypervariable region, and Y-chromosome studies by FISH, revealing complete donor chimerism.
In June 1995 the patient presented with fever, left upper facial pain, left periorbital cellulitis and a black area on left nasal mucosa. Biopsy of the nasal mucosa revealed numerous fungal hyphae with a branching pattern typical of mucormycosis. Rhizopus spp. was isolated in microbiological cultures. Peripheral blood was normal and biochemical testing showed hyperglycemia (260 mg/dl) not previously present. X-ray revealed an opacity in the sinus, and CT scan showed left maxillary sinus opacification with inflammation of the ethmoidal, frontal and sphenoidal sinus mucosa. Steroid treatment was discontinued, and liposomal amphotericin B (AmBisome 3 mg/kg daily; NeXstar Pharmaceuticals, Ireland) was initiated. Radical surgery was undertaken and left maxillary sinus antrectomy and turbi-nate exenteration was performed. A month later, a CT scan revealed persistence of the maxillary antrum mass, ethmoidal involvement and tumefaction of the intrinsic muscles of the eye. Three further surgical debridements were performed until the infection was controlled. After 4 months of treatment, amphotericin B was withdrawn (total dose given 12 g). The patient developed mild renal failure (creatinine peak level 2 mg/dl) due to treatment toxicity. After 2 years and 5 months from DLI, he is still in morphologic, cytogenetic and molecular remission, with complete chimerism.
Discussion
Mucormycosis is a term used to describe the diseases caused by fungi of the family Mucoraceae (Absidia, Apophysomyces, Mucor, Rhizomucor and Rhizopus). 5 The common portal of entry for human infections is via an inhaled route. 1, 5 The most characteristic feature of mucormycosis is invasion of a blood vessel by hyphae resulting in hemorrhage, thrombosis, infarction and necrosis of tissue. 1, 2, 5 It is an acute, rapidly progressive infection that occurs in several categories of patients including those with poorly controlled diabetes mellitus, hematological malignancies with neutropenia and receiving steroid therapy, acquired immunodeficiency syndrome, those undergoing organ transplantation and patients on dialysis receiving desferrioxamine. 1, 2, 5, 6, 7 The rhinocerebral form of disease is most commonly identified in these patients. Sinonasal, pulmonary, cutaneous, gastrointestinal, cerebral, disseminated and miscellaneous forms have also been described 2, 8 and mucormycosis can complicate the course of patients undergoing BMT. 1 Several risk factors for developing mucormycosis, such as prolonged neutropenia, poorly controlled diabetes, prolonged use of steroids and impaired humoral immunity are usually present in patients undergoing BMT. 2 DLI is an effective therapy for post-BMT relapse of CML, AML and sporadic cases of other hematologic malignances 3, 4 by its immunomodulatory effect (GVL) 9 which is closely related to GVHD. 10 This, and the prolonged periods of pancytopenia compromise the success of DLI in a substantial number of patients. 4 This is the first case of mucormycosis described after DLI.
The factors most probably implicated in the development of mucormycosis in our patient are GVHD, prolonged use of CsA and steroids used in its treatment, steroid-induced diabetes present at mucormycosis diagnosis and the exposure to decaying material.
Early diagnosis, control of predisposing factors (GVHD response to treatment, withdrawal of immunosuppression and diabetes control), an accessible location which permitted repeated surgical debridement, and intensive antifungal treatment with high doses of amphotericin B, resulted in control of infection in our patient.
Despite the risk of renal toxicity, the mainstay of antifungal therapy for mucormycosis remains amphotericin B. Liposomal amphotericin B (AmBisome) is effective 11 in eradicating infection and allows the administration of high doses (total accumulated dose 12 g in our patient) with minimal toxicity. We must take into account that our patient has never been neutropenic and it is possible that prolonged neutropenia is the most important risk factor for disease development. Cases without neutropenia have been described, suggesting that cellular immunity 1,2,10 or another immune mechanism, could be important in the development of mucormycosis, especially in non-neutropenic patients with GVHD.
DLI is an effective treatment for patients who experience a relapse of leukemia after BMT but can predispose to severe fungal infections. Fungal infections should be considered a potential complication of DLI.
